Integrum AB (publ) (INTEG-B.ST)
SEK 18.65
(3.04%)
SEK 18.65
(3.04%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 22.07 Million SEK | 2.01% |
| 2022 | 21.63 Million SEK | 4.55% |
| 2021 | 20.69 Million SEK | 60.25% |
| 2020 | 12.91 Million SEK | 52.49% |
| 2019 | 8.46 Million SEK | -4.33% |
| 2018 | 8.85 Million SEK | 5.65% |
| 2017 | 8.37 Million SEK | -9.31% |
| 2016 | 9.23 Million SEK | 2.27% |
| 2015 | 9.03 Million SEK | 71.03% |
| 2014 | 5.28 Million SEK | -5.99% |
| 2013 | 5.61 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 19.96 Million SEK | -9.53% |
| 2023 FY | 22.07 Million SEK | 2.01% |
| 2023 Q1 | 22.46 Million SEK | 3.82% |
| 2023 Q4 | 22.07 Million SEK | -14.34% |
| 2023 Q3 | 25.76 Million SEK | 5.39% |
| 2023 Q2 | 24.44 Million SEK | 8.83% |
| 2022 Q2 | 18.03 Million SEK | 3.47% |
| 2022 Q4 | 21.63 Million SEK | 75.74% |
| 2022 FY | 21.63 Million SEK | 4.55% |
| 2022 Q1 | 17.42 Million SEK | -15.8% |
| 2022 Q3 | 12.31 Million SEK | -31.71% |
| 2021 Q3 | 13.42 Million SEK | -26.88% |
| 2021 Q2 | 18.36 Million SEK | 67.18% |
| 2021 Q1 | 10.98 Million SEK | -14.95% |
| 2021 FY | 20.69 Million SEK | 60.25% |
| 2021 Q4 | 20.69 Million SEK | 54.13% |
| 2020 Q3 | 9.03 Million SEK | -11.38% |
| 2020 FY | 12.91 Million SEK | 52.49% |
| 2020 Q4 | 12.91 Million SEK | 43.0% |
| 2020 Q2 | 10.19 Million SEK | 27.25% |
| 2020 Q1 | 8 Million SEK | -5.44% |
| 2019 Q4 | 8.46 Million SEK | 61.85% |
| 2019 FY | 8.46 Million SEK | -4.33% |
| 2019 Q1 | 5.39 Million SEK | -39.03% |
| 2019 Q2 | 6.32 Million SEK | 17.11% |
| 2019 Q3 | 5.23 Million SEK | -17.21% |
| 2018 Q4 | 8.85 Million SEK | 2.52% |
| 2018 FY | 8.85 Million SEK | 5.65% |
| 2018 Q1 | 6.93 Million SEK | -17.25% |
| 2018 Q2 | 9.54 Million SEK | 37.64% |
| 2018 Q3 | 8.63 Million SEK | -9.52% |
| 2017 FY | 8.37 Million SEK | -9.31% |
| 2017 Q2 | 9.09 Million SEK | 44.4% |
| 2017 Q1 | 6.29 Million SEK | -31.81% |
| 2017 Q3 | 7.83 Million SEK | -13.88% |
| 2017 Q4 | 8.37 Million SEK | 6.95% |
| 2016 Q4 | 9.23 Million SEK | -4.19% |
| 2016 Q3 | 9.64 Million SEK | 0.0% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 FY | 9.23 Million SEK | 2.27% |
| 2015 FY | 9.03 Million SEK | 71.03% |
| 2015 Q4 | 9.03 Million SEK | 0.0% |
| 2014 FY | 5.28 Million SEK | -5.99% |
| 2013 FY | 5.61 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -100.699% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.175% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.175% |
| Arcoma AB | 33.3 Million SEK | 33.725% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 93.305% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.324% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 92.114% |
| CellaVision AB (publ) | 212.32 Million SEK | 89.604% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -55.476% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -221.343% |
| C-Rad AB (publ) | 122.4 Million SEK | 81.967% |
| Duearity AB (publ) | 17.53 Million SEK | -25.915% |
| Dignitana AB (publ) | 37.56 Million SEK | 41.244% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -11.479% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.911% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -7.148% |
| Iconovo AB (publ) | 14.55 Million SEK | -51.663% |
| Luxbright AB (publ) | 7 Million SEK | -215.321% |
| Mentice AB (publ) | 163.55 Million SEK | 86.504% |
| OssDsign AB (publ) | 105.25 Million SEK | 79.03% |
| Paxman AB (publ) | 44.5 Million SEK | 50.408% |
| Promimic AB (publ) | 16.15 Million SEK | -36.623% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 64.495% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -3.736% |
| ScandiDos AB (publ) | 37.18 Million SEK | 40.642% |
| Sectra AB (publ) | 1.64 Billion SEK | 98.655% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 49.905% |
| Senzime AB (publ) | 58.06 Million SEK | 61.986% |
| SpectraCure AB (publ) | 14.97 Million SEK | -47.398% |
| Stille AB | 172.64 Million SEK | 87.215% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.398% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 91.191% |